

radio/chemo sensitizers/protectors,
retinoids
selective inhibitors of proliferation and migration
of endothelial cells,
5 selenium,
stromelysin inhibitors,
taxanes,
vaccines, and
vinca alkaloids.

10 The major categories that some preferred
antineoplastic agents fall into include antimetabolite
agents, alkylating agents, antibiotic-type agents,
hormonal anticancer agents, immunological agents,
interferon-type agents, and a category of miscellaneous
15 antineoplastic agents. Some antineoplastic agents operate
through multiple or unknown mechanisms and can thus be
classified into more than one category.

A first family of antineoplastic agents which may be
used in combination with the present invention consists of
20 antimetabolite-type antineoplastic agents. Antimetabolites
are typically reversible or irreversible enzyme
inhibitors, or compounds that otherwise interfere with the
replication, translation or transcription of nucleic
acids. Suitable antimetabolite antineoplastic agents that
25 may be used in the present invention include, but are not
limited to acanthifolic acid, aminothiadiazone,
anastrozole, bicalutamide, brequinar sodium, capecitabine,
carmofur, Ciba-Geigy CGP-30694, cladribine, cyclopentyl
cytosine, cytarabine phosphate stearate, cytarabine
30 conjugates, cytarabine ocfosphate, Lilly DATHF, Merrel Dow
DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine,
didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck

& Co. EX-015, fazarabine, finasteride, floxuridine, fludarabine phosphate, N-(2'-furanidyl)-5-fluorouracil, Daiichi Seiyaku FO-152, fluorouracil (5-FU), 5-FU-fibrinogen, isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, methotrexate, Wellcome MZPES, nafarelin, norspermidine, nolvadex, NCI NSC-127716, NCI NSC-264880, NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, stearate; Takeda TAC-788, thioguanine, tiazofurin, Erbamont TIF, trimetrexate, tyrosine kinase inhibitors, tyrosine protein kinase inhibitors, Taiho UFT, toremifene, and uricetin.

Preferred antimetabolite agents that may be used in the present invention include, but are not limited to, those identified in Table No. 3, below.

Table No. 3 . Antimetabolite agents

| Compound | Common Name/ Trade Name | Company | Reference | Dosage |
|---|----------------------------|---------|-----------|------------------|
| 1,3-Benzenediacetonitrile, alpha, alpha, alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)- | anastrozole ; ARIMIDEX® | Zeneca | EP 296749 | 1-mg/day |
| Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (+/-)- | bicalutamide; CASODEX® | Zeneca | EP 100172 | 50 mg once daily |

| Compound | Common Name/ Trade Name | Company | Reference | Dosage |
|---|--|-------------------------------------|------------|--|
| | capecitabine | Roche | US 5472949 | |
| Adenosine, 2-chloro-2'-deoxy-; 2-chloro-2'-deoxy- (beta)-D-adenosine) | cladribine; 2-CdA; LEUSTAT; LEUSTA-TIN®; LEUSTA-TIN® injection; LEUSTATINE®; RWJ-26251; | Johnson & Johnson | EP 173059 | 0.09 mg/kg/day for 7 days. |
| 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphinyl]-beta-D-arabinofuranosyl]-, monosodium salt | cytarabine ocfosfate; ara CMP stearyl ester; C-18-PCA; cytarabine phosphate stearate; Starasid; YNK-01; CYTOSAR-U® | Yamasa Corp | EP 239015 | 100 - 300 mg/day for 2 weeks |
| 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- | finasteride; PROPECIA® | Merck & Co | EP 155096 | |
| | fluorouracil (5-FU) | | US 4336381 | |
| Fludarabine phosphate. 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl) | fludarabine phosphate; 2-F-araAMP; Fludara; Fludara iv; Fludara Oral; NSC-312887; SH-573; SH-584; SH- | Southern Research Institute; Berlex | US 4357324 | 25 mg/m ² /d IV over a period of approximately 30 minutes daily for 5 consecutive days, |